

## Company Description

EirGenix (Taiwan Stock Code: 6589) provides high-quality and cost-effective contract development and manufacturing services. We work closely to support our clients in the development, analytical testing, and cGMP manufacturing of their biopharmaceuticals, from pre-clinical to commercial stage. EirGenix owns 2 cGMP facilities for mammalian cell-based and microbial-based manufacturing, and another commercial production facility with the scale of maximum twelve (12) 2,000 L single use bioreactor which maximum annual antibody production capacity is 1,000 kg.

EirGenix has received numerous national and international awards, and signed a license agreement with Sandoz AG to globally commercialize EirGenix's proposed trastuzumab biosimilar drug (EG12014) in April.

## Contact Information

<b>Name</b>	<b>Chih Jung Chang</b>	<b>Position</b>	Unit Vice President
<b>Tel</b>	<b>+886-2-7708 0123</b>		
<b>E-mail</b>	<b><a href="mailto:cjchang@eirgenix.com">cjchang@eirgenix.com</a></b>		
<b>Address</b>	No. 101, Lane 169, Kang Ning Street, Xizhi Dist., New Taipei City 22180, Taiwan (R.O.C.)		
<b>Sectors</b>	Biologics, Antibody, Biosimilar, Cgmp, PIC/S GMP, Contract Development & Manufacturing Service (CDMO), Cell Line Development, Cell Banking, QC Analysis, Antibody Drug Conjugate (ADC)		